Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance.

Future alternatives to the presently accepted in vitro paradigm of prediction of intrinsic clearance, which could be used earlier in the drug discovery process, would potentially accelerate efforts to identify better drug candidates with more favorable metabolic profiles and less likelihood of failure with regard to human pharmacokinetic attributes. In this study we describe two computational methods for modeling human microsomal and hepatocyte intrinsic clearance data derived from our laboratory and the literature, which utilize pharmacophore features or descriptors derived from molecular structure. Human microsomal intrinsic clearance data generated for 26 known therapeutic drugs were used to build computational models using commercially available software (Catalyst and Cerius(2)), after first converting the data to hepatocyte intrinsic clearance. The best Catalyst pharmacophore model gave an r of 0.77 for the observed versus predicted clearance. This pharmacophore was described by one hydrogen bond acceptor, two hydrophobic features, and one ring aromatic feature essential to discriminate between high and low intrinsic clearance. The Cerius(2) quantitative structure activity relationship (QSAR) model gave an r(2) = 0.68 for the observed versus predicted clearance and a cross-validated r(2) (q(2)) of 0.42. Similarly, literature data for human hepatocyte intrinsic clearance for 18 therapeutic drugs were also used to generate two separate models using the same computational approaches. The best Catalyst pharmacophore model gave an improved r of 0.87 and was described by two hydrogen bond acceptors, one hydrophobe, and 1 positive ionizable feature. The Cerius(2) QSAR gave an r(2) of 0.88 and a q(2) of 0.79. Each of these models was then used as a test set for prediction of the intrinsic clearance data in the other data set, with variable successes. These present models represent a preliminary application of QSAR software to modeling and prediction of human in vitro intrinsic clearance.

[1]  S. Ekins,et al.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.

[2]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[3]  D. Greenblatt,et al.  Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. , 1996, Journal of clinical psychopharmacology.

[4]  I Skånberg,et al.  In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.

[5]  C. Waller,et al.  Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[6]  S. Ekins,et al.  Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[7]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[8]  B. Hoener,et al.  Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.

[9]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[10]  S. Ekins,et al.  Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[11]  T Lavé,et al.  Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.

[12]  J. Houston,et al.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. , 1999, British journal of clinical pharmacology.

[13]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[14]  B. Ring,et al.  The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies , 1995, Toxicologic pathology.

[15]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[16]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[17]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  M. Bayliss,et al.  Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.

[19]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[20]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[21]  B. Ring,et al.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development. , 1993, Drug metabolism reviews.

[22]  A. Vickers,et al.  The biotransformation of the ergot derivative CQA 206-291 in human, dog, and rat liver slice cultures and prediction of in vivo plasma clearance. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[23]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[24]  S. Ekins Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. , 1996, Drug metabolism reviews.

[25]  J. Houston,et al.  Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[26]  J. Magdalou,et al.  Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. , 1999, The Journal of pharmacology and experimental therapeutics.